益菌研發

益菌研發

Research and Development
我們的品牌價值是建立在大量科學證據上

源自人體天然A尚好

比菲德氏菌 (Bifidobacterium) 為最古老的益生菌種，已與人類相伴數十萬年，堪稱人類最忠實的好菌，嬰兒出生後腸道中有 90%為比菲德氏菌，在免疫力尚未完全建立前，作為嬰幼兒的天然防護罩，因此又有「寶寶益生菌」或 「母嬰益生菌」的美名，但隨著年紀增長該菌數量有可能因為不良飲食、生活習慣而驟減；與其它益生菌不同，比菲德氏菌篩選自人體，且要在模擬腸道的厭氧環境中培養，世界上僅有極少數製造商能生產，最知名的是比菲德氏教父池根億教授以比菲德氏命名的韓國 bifido 公司。
人體的比菲德氏菌數量會從出生時隨著年齡增長慢慢減少
最初>90%的比菲德氏菌，隨年紀增長、不良飲食、作息紊亂等因素而驟減

比菲德氏教父

  • 國際知名益生菌專家
  • 國立首爾大學畢業
  • 美國路易斯安那州立大學 (Louisiana State University) 博士學位
  • 目前是首爾大學食品科學及營養的殿堂級教授
畢生投入人體天然菌之研究，堅持最適合人體食用的益生菌並須取自於腸道而不是外部環境，很多益生菌即使標榜菌數高，但不適合腸道定殖，反被壞菌競爭後排空。
首爾大學池根億教授
30
年開發
250+
篇文獻
80+
項專利
自 1988 年起，Bifido 的池根億教授便專注於微生物的研究，並領導首爾大學核心研究團隊與韓國各大醫院和研究機構進行合作研究，成功找出最優質的人體天然菌－比菲德氏，且篩出強悍的菌株，在微生物的領域中，曾發表超過 250 篇科學論文，獲得 80 項專利，是微生物組領域中經驗豐富的頂級專家。並在 1999 年創立 bifido 公司，打造巨大的生物反應器，可模擬人體腸道環境來培養益生菌，建造全世界最大的比菲德氏王國，在 2018 年於韓國科斯達克 KOSDAQ 股票上市，成為首家微生物發酵廠與 SAMSUNG、Hyundai、LG、SK 海力士等大型企業並列的高科技股公司。

腸道模擬器

比菲德氏菌(Bifidobacterium)不像一般的乳酸菌可輕易的從環境中取得，必須在模擬腸道的無氧的環境中培養，從菌株分離、篩選、試產及量產，均維持一條龍的無氧作業環境難度極高!

以池根億教授為首的 bifido 團隊，建構頂尖的比菲德氏菌篩菌平台，並打造出模擬人體腸道環境的生物反應器，所以能培養出最適合人體的比菲德氏菌。

bifido 歷史

bifido 從一間新創益生菌公司，到規模化生產模擬腸道無氧環境的工廠，再到韓國那斯達克 KOSDAQ 股票上市，建立全球最大的比菲德氏王國，僅花不到 20 年的時間，堪稱韓國生技界的奇蹟。

50 倍附著力

bifido 的比菲德氏菌經實驗證實，對於腸細胞的附著能力相較於其它公司所生產的比菲德氏菌，最高可強過 50 倍之多。
bifido 公司的比菲德氏菌經實驗證實，對於腸細胞的附著能力與他牌生產的比菲德氏菌相比，最高強過50倍之多。

10 倍增殖力

bifido 公司所篩選的比菲德氏菌經臨床佐證，食用 1 個月，可以讓腸內比菲德氏菌數量激增 10 倍。
bifido 公司所篩選的比菲德氏菌經臨床佐證，食用 1 個月，可以讓腸內比菲德氏菌數量激增 10 倍。
application-probio

22 項專利認可

專利編號
標題
10-0554346
A new anti-cancer polysaccharide from the genus bifidobacterium.
10-0635354
Composition for Prevention and Treatment of Food Allergy containing Bifidobacterium bifidum BGN4 as Active Ingredient.
10-1920219
Composition comprising bifidobacteria for preventing or treating of obesity.
10-1037778
Culture medium containing phytic acid for cultivation of Bifidobacterium bifidum BGN4 and method for
production of Bifidobacterium bifidum BGN4 polysaccharide using the medium.
10-1893803
Composition comprising bifidobacteria for preventing or treating of fatty liver.
10-1346739
Multiplex primer sets for detection of Bifidobacterium bifidum BGN4.
10-0492455
Bifidobacterium longum AR81 enabling inhibition of rotavirus and active protein separated therefrom.
10-1753243
Primer set for specific detection of Bifidobacterium longum BORI and method for detection of Bifidobacterium
longum BORI thereby.
10-2023700
Composition for prevention or treatment of rheumatoid arthritis with Bifidobacterium.
US 010617725B2
Composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis.
10-0492455
Bifidobacterium longum RAPO for improvement, prevention or treatment of rheumatoid arthritis and composition comprising the same.
10-0442205
Bifidobacterium lactis producing β- glucosidase andmethod for converting isoflavon into isoflavon
agluconusing the same.
10-1266557
Bifidobacterium animalis BF8 (KFCC11506P) against pathogenic Enterobacter(Cronobacter) sakazakii and food composition therefrom.
10-1163101
Food composition containing the Scutellaria baicalensis George biologically converted by lactic acid bacteria or lysate of lactic acid bacteria with anti-allergenic effect.
10-1499115
Method for production of fucosyl oligosaccharides with Bifidobacterium longum RD 47.
10-1581440
Bifidobacterium longum RD 47, method for production of galactosidase from Bifidobacterium longum and
galactooligosaccharide therefrom.
10-2082315
Composition of prebiotics with butyryl-fructooligosaccharides.
US11096951B2
Prebiotic composition containing butyryl-fructooligosaccharides.
10-2253283
Method for production of human EGF with Bifidobacterium bifidum and composition thereof.
10-2314736
Composition for improvement of skin inflammation and intensification of skin barrier.
10-2343938
Composition for improving inflammation containing recombinant Bifidobacterium bifidum BGN4.
10-2362828
Composition for improvemnet, prevention or treatment of kidney injury with Bifidobacterium bifidum BGN4.
application-probio

50+ 篇文獻發表

如需完整文獻，歡迎聯繫!
研究類型
功效
年分
標題
細胞
免疫調節
2002
Cytoskeleton Reorganization and Cytokine Production of Macrophages by
Bifidobacterial Cells and Cell-free Extracts.
細胞
免疫調節
2005
Modulatory Activity of Bifidobacterium sp. BGN4 Cell Fractions on Immune Cells.
細胞
免疫調節
2012
Probiotic Modulation of Dendritic Cells Co-cultured with Intestinal Epithelial Cells.
細胞
抗發炎
2021
Lysed and disrupted Bifidobacterium bifidum BGN4 cells promote anti-inflammatory activities in lipopolysaccharide-stimulated RAW 264.7 cells.
細胞
抗發炎
2021
Production of biologically active human interleukin‑10 by Bifidobacterium bifidum BGN4.
動物
抗肥胖
2016
Anti-obese Effects of Two Lactobacilli and two Bifidobacteria on ICR mice fed on a High Fat Diet.
動物
抗過敏
2005
Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model.
動物
抗過敏
2005
Timing of Bifidobacterium administration influences the development of allergy to ovalbumin in mice.
動物
抗過敏
2006
Effect of viability and integrity of Bifidobacterium on suppression of allergy in mice.
動物
抗過敏
2005
Regulatory Effect on Specific Ige Response of Bifido Bacterium Bifidum(bgn4 Strain) in Murine Model of Peanut Allergy.
動物
抗過敏
2008
Effect of Oral Probiotics (Bifidobacterium lactis AD011 and Lactobacillus acidophilus AD031) Administration on Ovalbumin-Induced Food Allergy Mouse Model.
臨床
抗過敏(特應性皮膚炎)
2011
Clinical Effects of Probiotics are Associated with Increased Transforming Growth Factor-β Responses in Infants with High-Risk Allergy.
臨床
抗過敏(濕疹)
2010
Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus ) in the primary prevention of eczema a double‐blind, randomized, placebo‐controlled trial.
臨床
抗癌
2004
Anticancerogenic effect of a novel chiroinositol-containing polysaccharide from Bifidobacterium bifidum BGN4.
細胞
抗癌
2009
Enhancement of Anti-tumorigenic Polysaccharide Production, Adhesion, and Branch Formation of Bifidobacterium bifidum BGN4 by Phytic Acid.
臨床
抗輪狀病毒
2017
The Efficacy of Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 Probiotic Treatment in Infants with Rotavirus Infection.
細胞
抗輪狀病毒
2019
The Anti-Rotaviral Activity of Low Molecular Weight and Non-Proteinaceous Substance from Bifidobacterium longum BORI Cell Extract.
細胞
腸道附著能力
2003
Characterization of Adhesion of Bifidobacterium sp. BGN4 to Human Enterocyte-Like Caco-2 Cells.
動物
促進比菲德氏菌的定殖
2017
Strain Specific Detection and Quantification of Probiotic Bifidobacterium bifidum BGN4 in Mouse Model and Positive Effect of B. bifidum BGN4 on Intestinal Microflora.
動物
改善發炎性腸道疾病
2017
Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4+ CD45RBhigh T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation.
臨床
改善腸躁症
2009
Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome.
臨床
改善潰瘍性腸炎
2009
The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.
臨床
腹瀉為主的腸躁症
2009
Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.
臨床
改善心情與認知功能
2021
Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community- Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
動物
認知功能(阿茲海默症模式)
2021
Administration of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI Improves Cognitive and Memory Function in the Mouse Model of Alzheimer’s Disease.
體內+體外
安全性
2009
Safety Evaluations of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI.
回顧性研究
新穎益生菌BGN4及BORI
2005
Development of Bifidobacterium sp. BGN4 and BORI with Novel Probiotic Activity.
回顧性研究
益生菌預防特應性皮膚炎
2009
Probiotics in Primary Prevention of Atopic Dermatitis.
回顧性研究
BGN4 功能及營養應用
2016
Review on Bifidobacterium bifidum BGN4: Functionality and Nutraceutical Applications as a Probiotic Microorganism.
動物
延緩腦部老化
2022
Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI promotes neuronal rejuvenation in aged mice.
臨床
改善腸道發炎
2022
Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus ) in the primary prevention of eczema a double‐blind, randomized, placebo‐controlled trial.
臨床
降低炎症反應
2022
The effect of probiotic supplementation on systemic inflammation in dialysis patients.
© 本網頁中的公司名、產品名、商標、專利、認證、實驗數據及說明受智慧財產權法保護，未獲授權請勿複製、引用或公開。 本網頁內容未經衛福部或FDA證實，不得作為功效宣稱、診斷、治療或預防疾病用途，僅供內部研究評估，請勿做任何商業用途。 本網頁內容不代表授權使用本公司或他人之智慧財產權。 終端產品標示、文宣、廣告等須遵循衛福部相關規範，使用本網頁內容產生之相關風險或責任應自行承擔。 These statements have not been evaluated by FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
臻於完美，止於至善
crossmenuchevron-upchevron-downcross-circle